logo

- Gains recognition for contributing to the development of the biopharma industry with expertise in antibody research and global clinical research capabilities.

- Continues its efforts to develop innovative medicines by investing over 10% of its annual revenue into R&D projects.

- Sets a success model by partnering with global entities to develop treatments in therapeutic areas including autoimmune, ophthalmology, and neuro immunology through open collaboration.

SEOUL, South Korea, April 19, 2024

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, was awarded the 2024 National Industry Awards in Research and Development.

Organized by the Institute for Industrial Policy Studies (IPS) and sponsored by the Ministry of Trade, Industry, and Energy of Korea, the National Industry Awards recognize companies with significant contributions to national industrial progress. 

Renowned for its excellence in R&D, HanAll was acknowledged for its expertise in antibodies and robust global clinical research capabilities, driving breakthroughs in the biopharma industry.

"We are deeply honored to receive the 2024 National Industry Award for Research and Development excellence," said Hye Kyung Ahn, Director of the Bio Research Center, Suwon, Korea.

“This recognition reflects our steadfast commitment to R&D to develop innovative medicines for patients. We are dedicated to pushing the boundaries of innovation and providing impactful solutions to enhance patient lives worldwide," she added.

In line with its steadfast pursuit of excellence, HanAll invests over 10% of its annual revenue into R&D projects, ensuring continual progress in its mission to provide innovative treatments to patients worldwide.

HanAll also established a benchmark for success by engaging in strategic partnerships with global entities to develop treatments for conditions with high unmet needs, including autoimmune diseases, dry eye, and Parkinson’s disease.

Moving into its next 50 years of innovation, HanAll plans to further expand its efforts to cultivate R&D talents and promote open collaboration.

About HanAll Biopharma

HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with a presence in Korea, the USA, Japan, and Indonesia with a mission of making meaningful contributions to patients' lives by introducing innovative, impactful medicines to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in the areas of endocrine, circulatory, and urologic diseases for over 50 years.

HanAll has also expanded its focus to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. Its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials across the world for the treatment of autoimmune diseases including myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves’ disease (GD). Another main asset, HL036 (INN: tanfanercept), a TNF inhibitor protein, is being evaluated in Phase 3 clinical studies in the US and China for the treatment of dry eye disease. For further information, visit our website and connect with us on LinkedIn. For any media inquiries, please contact HanAll PR/IR (pr@hanall.com, ir@hanall.com).

Disclaimer Statement 

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should," and include statements HANALL (the company, we) makes concerning its 2024 business and financial outlook and related plans; the therapeutic potential of its product candidates; the intended results of its strategy and the company, and its collaboration partners', advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts; the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. These may include various significant factors, such as our expectations regarding the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities, and regulatory approval requirements. In addition, performance may be affected by our reliance on collaborations with third parties, estimating the commercial potential of our product candidates, our ability to obtain and maintain protection of intellectual property of technologies and drugs, our limited operating history, and our ability to obtain additional funding for operations and to complete the development and commercialization of product candidates. A further list and description of these risks, uncertainties, and other risks can be found in Korea Stock Exchange (KRX) filings and reports, including in our most recent annual report as well as subsequent filings and reports filed by the company with the KRX. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. We undertake no obligation to publicly or revise the information in this press release, including any forward-looking statements, except as may be required by Korean law and regulations.